Back

ISPOR 2022 - Annual Meeting of International Society for Pharmacoeconomics and Outcomes Research

May 15 - May 18, 2022 | National HarborMDUS

LARVOL is not affiliated with Annual Meeting of International Society for Pharmacoeconomics and Outcomes Research and all trademarks, logos, and brand names are property of their respective owners

Showing 56 abstracts linked to Trials

Cost Effectiveness of Cabozantinib Plus Nivolumab As First-Line Treatment for Renal Cell Carcinoma

  • On-demand

Randomized Clinical Trial Replication for Cardiovascular Outcomes of EMPA-Reg Trial: Retrospective Cohort Study

  • Poster

Health and Economic Outcomes of Botulinum Toxin-a Products for Adult Patients with UPPER LIMB Spasticity in a Real-World Setting

  • Poster

Modeling Survival of People with Cystic Fibrosis (PWCF) Aged ≥6 Years Heterozygous for the F508DEL Mutation with a Minimal Function Mutation (F/MF) in Brazil Treated with Elexacaftor/Tezacaftor/Ivacaftor and Ivacaftor (ELX/TEZ/IVA)

  • Poster

Comparing the Cost-Effectiveness of the Otago Exercise Programme Among Older Women and Men: A Secondary Analysis of a Randomized Controlled Trial

  • Poster

Numbers Needed to Treat and Costs per Improved Outcome Among Treatments for Myasthenia Gravis

  • Poster